B
Bristol-Myers Squibb
Discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals
About Bristol-Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company operates primarily in the healthcare and pharmaceutical markets, focusing on areas such as oncology (cancer treatment), immunology (autoimmune diseases), and cardiovascular diseases.
BMS serves a diverse range of clients, including hospitals, healthcare providers, and patients. The company’s business model revolves around extensive research and development (R&D) to create new drugs and therapies. This involves significant investment in scientific research to explore potential treatments and bring them to market. BMS makes money by selling these innovative medicines and therapies once they receive regulatory approval.
The company is also involved in the production of generic drugs, which are more affordable versions of previously approved innovative medicines. These generics contain the same active ingredients and meet stringent quality and safety standards. By offering both innovative and generic medicines, BMS aims to increase the availability of affordable healthcare solutions.
BMS places a strong emphasis on sustainability and corporate responsibility. The company is committed to achieving Environmental, Social, and Governance (ESG) goals, which include building trust with stakeholders and making a positive impact on patients and the world. BMS also supports the establishment of regulatory pathways for biosimilars, which are highly similar to already approved biological medicines, ensuring they meet efficacy and safety standards.
In summary, Bristol Myers Squibb is a leading biopharmaceutical company focused on developing and delivering innovative and affordable medicines to improve patient outcomes. The company’s commitment to research, sustainability, and regulatory compliance positions it as a key player in the global healthcare market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1887
- Headquarters
- Lawrence Township, United States
- Listing
- IPO 1929
- Employees
- 38,633
- Open positions
- 488
- Dealroom signal
- 71.3/100
- Industry
- Health, Transportation
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Charity, Performance Management, Tourism, Biotechnology, Drug Development, Anti-Fraud, Pay Per Result, Horizon Europe
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 131 companies, latest Jul 2026
- Capital deployed
- $7.5B
- Preferred round
- SERIES B
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Nov 2025 | $5B | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Feb 2024 | $13B | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Bristol-Myers Squibb is 790K monthly website visits, down 10.2% over the last three months. Bristol-Myers Squibb's team grew 30.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 BayerGlobal enterprise with core competencies in the Life Science fields of health care and agriculture |
Leverkusen, Germany | Operational | 92,539 | — | $85B |
 Seven BridgesA cloud-based environment for conducting bioinformatic analyses |
New Belgrade Urban Municipality, Serbia | Acquired | |||
 NumaresIn vitro diagnostic tests and test systems for high-throughput operation in routine labs, and clinical research |
Regensburg, Germany | Operational | |||
 Micar Innovation (Micar21)Micar Innovation is a drug discovery factory |
Sofia, Bulgaria | Operational | |||
 Fabric GenomicsGlobal healthcare platform for genomic data analysis - Formerly Omicia |
San Francisco, United States | Acquired | |||
 SoluBestBiotech & Life Sciences |
Ness Ziyyona, Israel | Operational | |||
 FF PharmaBiopharmaceutical drug research company |
Utrecht, Netherlands | Operational | |||
 CergentisBioinformatical analysis of genes sequencing |
Utrecht, Netherlands | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
RatiotxBoston, United StatesSpecializing in the development of targeted radiotherapeutics for the treatment of cancer
$280Mvaluation
Beeline MedicinesStamford, United StatesPrecision therapies for autoimmune and inflammatory diseases.
$1.7Bvaluation
Precede BiosciencesBoston, United StatesLiquid biopsy platform profiling disease-defining transcriptional biology
$254Mvaluation
Link Cell TherapiesSouth San Francisco, United StatesA True CAR T Cell AND-Gate
$120Mvaluation
Orbital TherapeuticsSan Francisco, United StatesAims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease
$1.5Bvaluation
Dispatch BioPhiladelphia, United StatesCloud-powered platform for infectious disease diagnostics
$864Mvaluation
GlycoEraSchlieren, SwitzerlandGlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications
$520Mvaluation
Allyx TherapeuticsNew Haven, United StatesInnovative oral therapies preserving synapses for neurodegenerative disease patients
$106Mvaluation
2seventybioCambridge, United StatesImmuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment
$336Mvaluation
Light Horse TherapeuticsSan Diego, United StatesPrecision gene editing for small molecule drug discovery
$248Mvaluation
Be BioCambridge, United StatesEngineering b cell medicines to improve care for serious diseases
$650Mvaluation
Nuvig TherapeuticsRedwood City, United StatesAdvancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function
$644Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
EuroFinance
Series B and later1 investor entered at this stage
Carl Icahn
Other known investors5 additional known investors
Accelerate Okanagan
EW Healthcare Partners
Kleiner Perkins
Medicon Village
RA Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bristol-Myers Squibb on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bristol-Myers Squibb’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.